PET/CT心肌血流评估对心脏移植血管病变进展和临床结局具有预后价值
该研究评估了13N-氨PET/CT心肌灌注显像对心脏移植受者心脏移植血管病变(CAV)的预后价值。344例受者中位随访4.8年,PET CAV 0/1级对后续有创冠状动脉造影发现国际心肺移植学会CAV 2/3级的阴性预测值在600、900、1200天分别为0.93、0.95、0.95。PET CAV 2/3级与全因死亡风险升高相关(HR 2.86,95%CI 1.36-6.00,P=0.006)。
要点
- PET CAV 0/1级对600、900、1200天后续ICA发现ISHLT CAV 2/3级的NPV分别为0.93、0.95、0.95。
- PET CAV 2/3级较PET CAV 0级全因死亡风险升高(HR 2.86,95%CI 1.36-6.00,P=0.006)。
- 135例稳定ISHLT CAV患者敏感性分析中,PET CAV 2/3级仍与死亡或再移植风险升高相关(HR 3.20,95%CI 1.18-8.69,P=0.03)。
核心结论
- PET/CT联合心肌血流储备无创评估CAV可提供预后信息,并对最长4年内发生中重度CAV具有较高阴性预测值。
- 作者认为,这些数据提示对某些患者可延长有创筛查间隔。
研究设计与样本
- 研究纳入344例接受PET/CT评估CAV的心脏移植受者,中位随访4.8年。
- PET/CT与有创冠状动脉造影(ICA)采用经验证的评分标准进行分级。
- CAV进展通过患者内序列评估:基线ICA、间期PET/CT心肌血流储备、后续ICA。
- 分析纳入ICA间隔为600、900、1200天的序列,分别评估CAV发生的阴性预测值(NPV)。
主要发现
- PET CAV 0/1级对后续ICA发现ISHLT CAV 2/3级的NPV在600、900、1200天分别为0.93、0.95、0.95。
- 与PET CAV 0级相比,PET CAV 2/3级与全因死亡风险升高相关(HR 2.86,95%CI 1.36-6.00,P=0.006)。
- PET CAV 1级风险数值升高但未达统计学显著(HR 2.03,95%CI 0.99-4.15,P=0.054)。
- 在135例连续ICA显示ISHLT CAV稳定的患者敏感性分析中,PET CAV 2/3级仍与死亡或再移植风险升高相关(HR 3.20,95%CI 1.18-8.69,P=0.03)。
关键数值与推荐
- PET CAV 0/1级对600天后续ICA发现ISHLT CAV 2/3级的NPV为0.93。
- PET CAV 0/1级对900天后续ICA发现ISHLT CAV 2/3级的NPV为0.95。
- PET CAV 0/1级对1200天后续ICA发现ISHLT CAV 2/3级的NPV为0.95。
- PET CAV 2/3级较PET CAV 0级全因死亡风险HR 2.86(95%CI 1.36-6.00,P=0.006)。
- 敏感性分析中PET CAV 2/3级与死亡或再移植风险HR 3.20(95%CI 1.18-8.69,P=0.03)。
临床怎么用
- 作者认为,这些数据提示对某些患者可延长有创筛查间隔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiac allograft vasculopathy (CAV) causes impaired blood flow in both epicardial vessels and microvasculature and remains a leading cause of posttransplant morbidity and mortality. This study examined the prognostic value and outcomes of CAV, assessed by 13N-ammonia PET/CT myocardial perfusion imaging in heart transplant recipients. Methods: PET/CT and invasive coronary angiography (ICA) were graded using validated scales. CAV progression was assessed using intrapatient sequences: baseline ICA, interval PET/CT with myocardial blood flow reserve, and subsequent ICA. Intervals between ICAs of 600, 900, and 1200 d were included, and for each, the negative predictive value (NPV) of CAV development was assessed. Results: In total, 344 heart transplant recipients underwent PET/CT for CAV assessment with a median follow-up of 4.8 y. PET CAV grade 0/1 had an NPV of 0.93, 0.95, and 0.95 at each respective time point for developing an International Society for Heart and Lung Transplantation CAV 2/3 on subsequent ICA. Compared with PET CAV 0, PET CAV 2/3 was associated with a 2.9-fold increased risk of all-cause mortality (hazard ratio, 2.86; 95% CI, 1.36-6.00; P = 0.006). PET CAV 1 had a numerically increased risk (hazard ratio, 2.03; 95% CI, 0.99-4.15; P = 0.054). In a sensitivity analysis of 135 patients with stable International Society for Heart and Lung Transplantation CAV over successive ICA, PET CAV 2/3 remained associated with increased risk of death or retransplantation (hazard ratio, 3.20; 95% CI, 1.18-8.69; P = 0.03). Conclusion: Noninvasive CAV assessment by PET/CT and myocardial blood flow reserve provides prognostic information and robust NPVs for development of moderate to severe CAV over intervals up to 4 y. These data suggest that, for certain patients, intervals between invasive screenings may be extended.
引用
- Prasad N, Harris E, DeFilippis EM, et al. PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes. J Nucl Med. 2025. PMID: 39819689. doi:10.2967/jnumed.124.268713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。